Captrust Financial Advisors Biocryst Pharmaceuticals Inc Transaction History
Captrust Financial Advisors
- $30.9 Billion
- Q2 2024
A detailed history of Captrust Financial Advisors transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Captrust Financial Advisors holds 13,630 shares of BCRX stock, worth $106,041. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,630
Previous 13,285
2.6%
Holding current value
$106,041
Previous $67,000
25.37%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding BCRX
# of Institutions
260Shares Held
173MCall Options Held
397KPut Options Held
444K-
Black Rock Inc. New York, NY20MShares$155 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.8MShares$146 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.6MShares$97.8 Million1.06% of portfolio
-
State Street Corp Boston, MA9.35MShares$72.7 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.83MShares$68.7 Million4.25% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.45B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...